Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc has reported a 13% beneficial ownership stake in Immix Biopharma, Inc. through its various investment management subsidiaries.

Janus Henderson Group plc has reported beneficial ownership of 3,890,589 shares, representing 7.2% of the common stock of Tyra Biosciences, Inc., as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 7,193,433 shares, representing 8.7% of the outstanding common stock of PTC Therapeutics, Inc., as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5,207,011 shares, representing 9.6% of Protara Therapeutics, Inc.'s common stock, as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 7,108,488 shares, representing 8.2% of the outstanding common stock of Olema Pharmaceuticals, Inc.

Janus Henderson Group plc has reported a 7.4% beneficial ownership stake in Lantheus Holdings, Inc. as of March 31, 2026.

Janus Henderson Group plc has reported a beneficial ownership of 6.9% in Janux Therapeutics, Inc., holding 4,196,409 shares as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 3,105,669 shares, representing 6.3% of the outstanding common stock of Jade Biosciences, Inc.

Janus Henderson Group plc has reported beneficial ownership of 4,802,002 shares, representing 9.1% of Immix Biopharma, Inc.'s common stock, as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 16,575,875 shares, representing 11.5% of Vaxcyte, Inc.'s common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Maze Therapeutics, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 8.8% of Madrigal Pharmaceuticals, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 7,265,253 shares, representing 8.3% of Ideaya Biosciences, Inc.'s common stock, as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 11.7% of Biohaven Ltd. common shares, totaling 17,534,612 shares, as of March 31, 2026.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 5,348,395 shares of Glaukos Corp. common stock, representing 9.2% of the class.

Janus Henderson Group plc has reported a beneficial ownership of 5.7% in Gildan Activewear Inc. common shares as of March 31, 2026.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 9.99% of Forte Biosciences, Inc. common stock.

Janus Henderson Group plc has reported beneficial ownership of 13,647,376 shares of Dyne Therapeutics Inc. common stock, representing 8.3% of the class.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 13,179,013 shares, representing 6.8% of the outstanding common stock of BridgeBio Pharma, Inc.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 760,141 shares, representing 7.2% of Bel Fuse Inc.'s Class B Common Stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 3,719,452 American Depositary Shares, representing 6.0% of the class, in Ascendis Pharma A/S.

Janus Henderson Group plc has reported beneficial ownership of 9.9% of Minerva Neurosciences, Inc. common stock, holding 4,307,759 shares.

Janus Henderson Group plc has reported beneficial ownership of 5.9% of Longeveron Inc.'s Class A Common Stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.1% of Bicara Therapeutics Inc.'s common stock, indicating a significant investment position.

Janus Henderson Group plc has reported a beneficial ownership of 5.3% in Tarsus Pharmaceuticals, Inc., holding 2,240,963 shares as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.4% of Stride, Inc.'s common stock as of March 31, 2026, holding 2,277,279 shares.

Janus Henderson Group plc has reported beneficial ownership of 5.5% of Edgewise Therapeutics, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.